Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

BACKGROUND: Hyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Zheng, Xin, Deng, Jin, Zhou, Junlin, Ou, Jihong, Hong, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347467/
https://www.ncbi.nlm.nih.gov/pubmed/35912897
http://dx.doi.org/10.1080/0886022X.2022.2094273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347467/
https://www.ncbi.nlm.nih.gov/pubmed/35912897
http://dx.doi.org/10.1080/0886022X.2022.2094273

Ejemplares similares